Labiotech.eu

How to Address the Challenges of Biologics Discovery and Development

The biologics industry is growing at an incredible rate. While its global market value was estimated at $236B in 2017, it is expected to rise to $310B by 2023. As key market players enter the field, competition is increasing. In recent years, the biologics industry has become more versatile and has moved from being primarily […]

November 27, 2019 - 6 minutesmins - By External Contributor

lupus autoimmune disease neutrophil citryll

More News! 26 Nov 2019

Rare Inflammatory Disease Drug Beats Immunosuppressants in Phase III

A small molecule drug developed by the US company ChemoCentryx and its Swiss partner Vifor Fresenius Medical Care Renal Pharma (VFMCRP) was more effective at treating a rare inflammatory vascular disease than current treatments in a phase III trial. The drug avacopan was trialed in 331 patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. This life-threatening condition […]

November 26, 2019 - 3 minutesmins - By Jonathan Smith

News and Trends 25 Nov 2019

Novartis Enters RNA Therapeutics with Medicines Company Merger

Novartis is to acquire The Medicines Company and its late-stage RNA interference drug designed to protect against cardiovascular disease in twice-yearly shots. Novartis will pay €8.8B ($9.7B) to acquire The Medicines Company, which is based in the US and focuses on developing the RNA drug inclisiran for the treatment of cardiovascular disease and renal impairment. […]

November 25, 2019 - 3 minutesmins - By Jonathan Smith

Jennie Ekbeck Umea Biotech Incubator e1575383377248

Interview 25 Nov 2019

Building a Life Science Industry from Scratch in a Small Swedish Town

Jennie Ekbeck has taken on the challenge of building Europe’s best life science incubator in Umeå, a small town in northern Sweden. Jennie Ekbeck became the CEO of the Umeå Biotech Incubator in 2012. Before that she was the CEO of a probiotics startup called Probac. “The reason why I applied to be the CEO […]

November 25, 2019 - 8 minutesmins - By Clara Rodríguez Fernández

News and Trends 22 Nov 2019

ViiV Healthcare Licenses Long-Acting Antibody to Attack Hidden HIV

The UK company ViiV Healthcare will begin a phase IIa trial of an antibody licensed from the National Institutes of Health in the US that could block HIV transmission for longer than current antiretroviral therapies. The antibody is currently in an ongoing phase I trial run by the National Institute of Allergy and Infectious Diseases, […]

November 22, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 21 Nov 2019

€37.4M Invested in Azeria Therapeutics’ Cancer Treatment Program

UK-based Azeria Therapeutics has raised a Series B investment round of €37.4M to fund development of novel breast cancer drugs targeting proteins called pioneer factors. The series B financing includes a €34.5M commitment from leading UK healthcare VC firm Syncona. The remainder was provided by the CRT Pioneer Fund — a specialist UK fund dedicated […]

November 21, 2019 - 3 minutesmins - By External Contributor

News and Trends 21 Nov 2019

Update: Swedish Medical Device Fails to Treat Spinal Cord Injury

Update (21/11/2019): The Swedish biotech BioArctic has terminated the clinical development of a biodegradable implant that is designed to treat spinal cord injury by encouraging the regrowth of nerve cells. The decision was made when an interim analysis in BioArctic’s phase I/II trial concluded that the treatment was ineffective. BioArctic will instead focus on developing […]

November 21, 2019 - 3 minutesmins - By Alexander Burik

More News! 20 Nov 2019

Spanish Researchers Produce Straws Made of Bacterial Bioplastic

An industry-academia collaboration in Spain has developed drinking straws based on a bioplastic produced by bacteria that are expected to enter the market in the next few months. The collaboration includes the company Ocenic Resins and the academic institutions Jaume I University and the Institute of Agrochemistry and Food Technology, all based in Spain. The […]

November 20, 2019 - 3 minutesmins - By Jonathan Smith

More News! 20 Nov 2019

€39M Series B to Fund Biopolymers for Surgery and Implants

The French company Tissium has raised a €38.8M Series B round to fund the development of polymers that can be used to repair blood vessels and nerves. Contributing to the round were newcomers to Tissium such as the European Investment Fund and returning investors such as the investment bank Bpifrance and French life sciences […]

November 20, 2019 - 2 minutesmins - By Jonathan Smith

crispr therapeutics vertex beta thalassemia

News and Trends 19 Nov 2019

CRISPR Cell Therapy Shows Early Promise for Treating Blood Disorders

CRISPR Therapeutics and its US partner Vertex Pharmaceuticals have released the first clinical results for a cell therapy made using the gene editing tool CRISPR/Cas9 in patients with genetic blood disorders. The interim results concern two patients enrolled in different phase I/II clinical trials testing the same therapy in two blood disorders: transfusion-dependent beta-thalassemia and […]

November 19, 2019 - 3 minutesmins - By Jonathan Smith

News and Trends 19 Nov 2019

US-French Deal to Tailor Ultrasound Therapy to Brain Cancer Patients

The French company CarThera has teamed up with the US firm Kiyatec to study the effects on individual patients of an ultrasound therapy to deliver brain cancer drugs to the brain. Under the agreement, Kiyatec will test the effects of chemotherapy on cells taken from CarThera’s ongoing phase I/II trial in patients with brain cancer. […]

November 19, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 18 Nov 2019

Update: Single-Shot Vaccine for Chikungunya Lasts for a Year in Phase I

Update (18/11/2019): French biotech Valneva has revealed additional phase I results concerning its experimental chikungunya vaccine; all 68 patients that were given a single injection of the vaccine showed sustained protection after 12 months. The company is currently running a phase II study and plans to launch a pivotal phase III trial next year. Update […]

November 18, 2019 - 3 minutesmins - By Jonathan Smith

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

How to Address the Challenges of Biologics Discovery and Development

Rare Inflammatory Disease Drug Beats Immunosuppressants in Phase III

Novartis Enters RNA Therapeutics with Medicines Company Merger

Building a Life Science Industry from Scratch in a Small Swedish Town

ViiV Healthcare Licenses Long-Acting Antibody to Attack Hidden HIV

€37.4M Invested in Azeria Therapeutics’ Cancer Treatment Program

Update: Swedish Medical Device Fails to Treat Spinal Cord Injury

Spanish Researchers Produce Straws Made of Bacterial Bioplastic

€39M Series B to Fund Biopolymers for Surgery and Implants

CRISPR Cell Therapy Shows Early Promise for Treating Blood Disorders

US-French Deal to Tailor Ultrasound Therapy to Brain Cancer Patients

Update: Single-Shot Vaccine for Chikungunya Lasts for a Year in Phase I

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!